Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

Launched by CHINESE PLA GENERAL HOSPITAL · Jul 7, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new imaging tool called 68Ga-XT771 to help doctors better diagnose two types of cancer: glioblastoma (a type of brain cancer) and clear cell renal cell carcinoma (a type of kidney cancer). The study will use a special scan called a PET/CT to see how well this new tool highlights cancer cells in the body. Researchers also want to make sure that 68Ga-XT771 is safe to use and understand how it moves and spreads through the body after being given.

Adults aged 18 and older who have been diagnosed with either glioblastoma or clear cell renal cell carcinoma may be able to join this study, as long as they don’t have allergies to the study drug or certain health conditions that would make participation unsafe. Pregnant or breastfeeding women cannot take part. If you join, you will receive the imaging agent and have PET/CT scans to help doctors see the cancer more clearly. The study is currently looking for volunteers, and participation could help improve cancer diagnosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma
• Exclusion Criteria:
• • 1. Known allergy to components of the investigational drug or its analogues 2. suspected to have a certain disease or condition that is not suitable for the study drug 3. Known pregnant or lactating women